New York, NY
Summary
This business focuses on the development of RNA therapeutics using advanced technologies such as Artificial Intelligence and Machine Learning. Their proprietary SpliceCore® software platform enhances the discovery of drug targets by analyzing RNA sequencing data, allowing for faster and more precise identification of therapeutic targets. The platform is particularly adept at detecting splicing variations, which are critical for developing effective RNA-based therapies. Additionally, they have a specialized branch, SpliceIO™, that targets tumor-specific neoepitopes for immunotherapy applications.
Based on content on envisagenics.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
10.2 years — Since Oct 2014
Web Hosting
Platform
E-Mail Provider
Microsoft Office 365
NAICS Code
541714
SIC 4 Digit Code
8731
SIC 2 Digit Code
87
Industry
1. Biotechnology and Pharmaceutical Development
2. Research and Development in Biotechnology (except Nanobiotechnology)
Vendor
Source
Microsoft
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|